Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CANbridge Approved for China Phase Ib/III Trial of Esophageal Cancer Drug

publication date: Aug 14, 2018

CANbridge Life Sciences, a Beijing in-licensing company, was approved to start a China Phase Ib/III clinical study of CAN017 in esophageal squamous cell cancer (ESCC). CANbridge in-licensed global rights (ex-North America) to the candidate from Aveo Pharma two years ago in a $134 million deal. The trial acceptance triggers a $2 million milestone payment to Aveo. Earlier this year, CANbridge started China trials of CAN008, a treatment for glioblastoma multiforme (GBM). More details....

Stock Symbol: (NSDQ: AVEO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.